TR201009397A2 - Rosuvastatin içeren farmasötik bileşimler. - Google Patents

Rosuvastatin içeren farmasötik bileşimler.

Info

Publication number
TR201009397A2
TR201009397A2 TR2010/09397A TR201009397A TR201009397A2 TR 201009397 A2 TR201009397 A2 TR 201009397A2 TR 2010/09397 A TR2010/09397 A TR 2010/09397A TR 201009397 A TR201009397 A TR 201009397A TR 201009397 A2 TR201009397 A2 TR 201009397A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
compositions containing
containing rosuvastatin
rosuvastatin
particles
Prior art date
Application number
TR2010/09397A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09397A priority Critical patent/TR201009397A2/tr
Priority to PCT/TR2011/000135 priority patent/WO2011139256A2/en
Priority to EP11725996A priority patent/EP2566465A2/en
Priority to PCT/TR2011/000249 priority patent/WO2012064307A1/en
Publication of TR201009397A2 publication Critical patent/TR201009397A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Abstract

Mevcut buluş etken madde olarak rosuvastatin ve/veya farmasötik olarak kabul edilebilir bir tuzunu içeren farmasötik partiküller ve bu partiküllerin ateroskleroz, hiperkolesterolemi, hiperlipoproteinemi, hipertrigliseridemi, miyokard enfarktüsü tedavisi ve/veya önlenmesinde kullanılacak bir ilacın üretiminde kullanılması ile ilgilidir.
TR2010/09397A 2010-05-04 2010-11-11 Rosuvastatin içeren farmasötik bileşimler. TR201009397A2 (tr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/09397A TR201009397A2 (tr) 2010-11-11 2010-11-11 Rosuvastatin içeren farmasötik bileşimler.
PCT/TR2011/000135 WO2011139256A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations
EP11725996A EP2566465A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations
PCT/TR2011/000249 WO2012064307A1 (en) 2010-11-11 2011-11-03 Pharmaceutical compositions comprising rosuvastatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09397A TR201009397A2 (tr) 2010-11-11 2010-11-11 Rosuvastatin içeren farmasötik bileşimler.

Publications (1)

Publication Number Publication Date
TR201009397A2 true TR201009397A2 (tr) 2012-05-21

Family

ID=45446165

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09397A TR201009397A2 (tr) 2010-05-04 2010-11-11 Rosuvastatin içeren farmasötik bileşimler.

Country Status (2)

Country Link
TR (1) TR201009397A2 (tr)
WO (1) WO2012064307A1 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201009399A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Hızlı çözünen efervesan rosuvastatin formülasyonları.
SI2844233T1 (sl) * 2012-05-01 2020-08-31 Althera Life Sciences, Llc Peroralna tableta, sestavljena iz fiksne kombinacije rosuvastatina in ezetimiba za zdravljenje hiperlipidemije in bolezni srca in ožilja
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
EP2692354A1 (en) 2012-08-03 2014-02-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Means for treating heart disease
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
US10413543B2 (en) 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2008015563A2 (en) 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
PL2309992T3 (pl) 2008-06-27 2018-05-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna zawierająca statynę
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations

Also Published As

Publication number Publication date
WO2012064307A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
TR201009397A2 (tr) Rosuvastatin içeren farmasötik bileşimler.
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
PH12015501156A1 (en) Pharmaceutical compositions
IN2013CN01340A (tr)
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MA44637B1 (fr) Composes hétérocycliques et leurs utilisations
PH12015502365B1 (en) Bace1 inhibitors
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX353061B (es) Nuevos comprimidos de meloxicam de baja concentracion.
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
JO3524B1 (ar) مستحضرات قَابِلة للحَقْنِ
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
MY160904A (en) Piperazines as antimalarial agents
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
TR201815617A2 (tr) Deksketoprofen içeren bir formülasyon.
IN2014CN04119A (tr)
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.